Clients in the News
BioClin Announces Series B Funding
Congratulations to BioClin Therapuetics for their recently announced Series B funding. BioClin is developing B-701, a highly specific human anti-FGFR3 antibody, for metastatic bladder cancer (urothelial cell carcinoma) and achondroplasia (dwarfism).
The company raised $30 million in this latest round, which will be used for the expansion of their Phase 1b/2 trial evaluating B-701 in combination with docetaxel, as well as initiating a Phase 1b/2 trial evaluating B-701 in combination with atezolizumab.
We wish BioClin, a long-time Aragen partner, continued success.
BioClin Press Releases
SutroMax Announces Series B Funding
Congratulations to SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, for their recently announced Series B funding.
The company raised $64 million in this latest round and plans to use the proceeds to advance its lead pneumococcal conjugate vaccine (PCV), which prevents invasive pneumococcal disease caused by Streptococcus pneumoniae, and accelerate the Company’s antigen discovery and early-stage development efforts in other disease areas.
We wish SutroVax, a long-time Aragen partner, continued success.
SutroVax Press Releases
Congratulations to ImmuNext for their recently announced two agreements:
- Hoffmann-La Roche Inc. (Roche) and ImmuNext announced a deal on Dec 1 that focused on the development of novel therapeutics that modulate the immune system for the treatment of inflammation and autoimmune diseases. Under the terms of the Roche agreement, ImmuNext will grant Roche a worldwide, exclusive license to develop and commercialize therapeutics that agonize the V-region immunoglobulin-containing suppressor of T-cell activation (VISTA) signaling pathway. VISTA is a negative checkpoint regulator.
- Sanofi and ImmuNext announced on January 9, 2017 an agreement focused on the development of a novel antibody with the potential to treat a range of autoimmune diseases including Lupus and Multiple Sclerosis. Under the terms of the agreement, ImmuNext will grant Sanofi an exclusive, worldwide license to develop and commercialize INX-021, a CD40L monoclonal antibody in preclinical development that suppresses the activity of a cellular pathway that is overactive in many autoimmune diseases. In addition, Sanofi and ImmuNext will initiate a research collaboration to support clinical trials.
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Other programs include a CD40 agonist for neoantigen cancer vaccines and a novel immuno-metabolic target, in each case establishing new classes of compounds.
We wish ImmuNext, a long-time Aragen partner, continued success.
Ready to find out how Aragen can help move your preclinical projects forward? Let’s Talk
Aragen Helps Innovent Stay in Fast Lane with Another Phase III Trial
Congratulations to Innovent Biologics, a leading biotech company based in Suzhou, China. The company has started a pivotal China Phase III clinical trial of its Humira biosimilar with a cell line generated by Aragen Bioscience. In the last twelve months, Innovent has been approved to start trials of four biologic drugs, a major achievement for the five-year old company. Innovent has quickly built up a portfolio of 12 molecules targeted towards indications in cancer, ophthalmology, autoimmune disorders, and cardiovascular diseases.
Aragen is pleased to be considered a key collaborator and wish them continued success.
For more information: